Method for jointly detecting lung cancer tumor marker based on flow cytometry

Abstract

The invention relates to a method for jointly detecting a lung cancer tumor marker based on flow cytometry. The method comprises the steps: step one, preparing a probe I; to be specific, preparing different types of fluorescent coded microspheres, marking the fluorescent coded microspheres with streptavidin, marking a capture antibody with a biotin, and carrying out coupling between the coded microspheres marked by streptavidin and the capture antibody marked by the biotin; step two, preparing a probe II; to be specific, marking a detection antibody with fluorescent dye; step three, carrying out multi-component biomarker detection by a fluorescence resonance energy transfer system in a reaction system; to be specific, in the reaction system, binding the probe I with the the probe II to form a fluorescence resonance energy transfer system under the condition of existing a tumor marker in an added sample, introducing the detected fluorescence intensities of the coded microspheres at the maximum emission wavelength of the probe II into a work curve to obtain concentrations of different types of tumor markers. The method has advantages of high sensitivity, fast implementation, high throughput, and low price.

Description

technical field [0001] The invention belongs to the field of immunodiagnosis and detection, and relates to a method for detecting tumor markers, in particular to a method for combined detection of lung cancer tumor markers based on flow cytometry. Background technique [0002] Tumor markers are chemical substances that reflect the existence of tumors. Their existence or quantitative changes can indicate the nature of tumors, so as to understand the histogenesis, cell differentiation, and cell functions of tumors, and help tumor diagnosis, classification, prognosis judgment, and treatment guidance. [0003] Since the same tumor may contain one or more markers, selecting some tumor markers with higher specificity for combined detection is beneficial to improve the sensitivity and specificity of tumor detection. [0004] Chemiluminescence immunoassay (CLIA) and electrochemiluminescence immunoassay (ECLIA) are common methods for detecting tumor markers in hospitals. CLIA has do...

AI Technical Summary

Problems solved by technology

CLIA has domestically produced instruments and reagents, but there are few types of monitoring and the penetration rate is low. At present, most hospitals still use instruments and reagents from imported manufacturers such as Roche and Beckman for testing.

The instruments and reagents of ECLIA are all imported, with high detection accuracy and simple operation. Therefore, large hospitals use this method to detect immune or biochemical indicators, but the detection is expensive.

Images